Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Adding either carboplatin or bevacizumab to a neoadjuvant regimen increased rates of pathologic complete response in triple-negative breast cancer patients.

A new study shows that in some cases, inhibiting the growth of primary tumors can promote the spread of tumor cells to other parts of the body.

A new study found that smoking increases the risk of estrogen receptor (ER)-positive breast cancer for young women.

Scientists have discovered that the injection of an engineered virus into triple-negative breast cancer cells may allow the cancers to be treated with therapeutic radioiodine, a treatment traditionally used to treat thyroid cancers.

This article aims to provide an overview of The Cancer Genome Atlas findings, with a particular focus on their potential biological relevance and therapeutic implications.

In order for malignancies to establish in metastatic sites, cancer cells must acquire attributes of those sites; specifically how this occurs in many cancers is relatively unknown, but a new study implicates the stroma of certain breast cancer tumors in the development of bone metastases.

Clearly there is no single therapy for all patients with TNBC, given the molecular heterogeneity of this subtype. However, new insights from further genomic analysis of TNBC suggest approaches to rational clinical trial design, and patients will undoubtedly benefit as we define the most appropriate therapeutic targets in management of this aggressive disease.


Subscribe to Triple-Negative Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.